Optimizing Topical Antifungal Therapy for Superficial Cutaneous Fungal Infections: Focus on Topical Naftifine for Cutaneous Dermatophytosis

November 2013 | Volume 12 | Issue 11 | Supplement Individual Articles | 165 | Copyright © November 2013

James Q. Del Rosso DO FAOCDa and Leon H. Kircik MDb

aTouro University College of Osteopathic Medicine, Henderson, NV;
Las Vegas Skin and Cancer Clinics/West Dermatology Group, JDRx Dermatology LLC, Henderson, NV
bMount Sinai Medical Center, New York, NY; Indiana University School of Medicine, Indianapolis, IN;
Physicians Skin Care, PLLC, Louisville, KY

The recent introduction of the 2% cream has been shown to be effective for tinea pedis and tinea cruris with once-daily application over a shorter duration (2 weeks) than what has been used in most cases with the 1% formulation. Although many of the available topical antifungal agents are effective and safe for CDIs and other SCFIs, naftifine offers fungicidal activity in most cases of CDIs, a rapid onset of clinical effect, and a therapeutic reservoir effect that may correlate with sustained clearance post-treatment.


Dr. Del Rosso has served as a consultant, advisory board participant, clinical investigator, and/or speaker for Allergan, Bayer Healthcare (Dermatology), Dermira, Eisai, Ferndale, Galderma, Innocutis, LeoPharma, Liquidia, Merz Pharmaceuticals, Onset Dermatologics, Pharmaderm, Primus, Promius Pharma, PuraCap, Quinnova, Ranbaxy, Taro, Unilever, Valeant Pharmaceuticals (Medicis, Consumer Care), and Warner-Chilcott.
Dr. Kircik has served as an advisor, investigator, consultant, and speaker for Allergan, Galderma, Bayer Healthcare, LeoPharma, Merz Pharmaceuticals, Promius Pharma, Quinnova, Stiefel/GSK, Taro, Valeant, and Warner Chilcott.
This article was reviewed by Merz Pharmaceuticals as required for internal review. No questions emerged regarding accuracy or explanation of content. The paper was finalized solely by the authors, who wrote the manuscript and maintained full control over all the content. After submission to the journal, only the JDD editorial staff, dermatologists involved in the official peer-review process, and authors were involved with communications related to this manuscript. All final decisions on content were determined by the authors.


  1. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50(5):748-752.
  2. Vena GA, Chieco P, Posa F, Garofalo A, Bosco A, Cassano N. Epidemiology of dermatophytoses: retrospective analysis from 2005 to 2010 and comparison with previous data from 1975. New Microbiol. 2012;35(2):207-213.
  3. Habif TP. Superficial fungal infections. In: Habif TP, ed.Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 5th ed. Philadelphia, PA: Mosby/Elsevier, 2010:409-439.
  4. Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. Skin diseases associated with Malassezia species.J Am Acad Dermatol. 2004;51(5):785-798.
  5. Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor.Dermatol Clin. 2003;21(3):413-429.
  6. Habif T. Superficial fungal infections. In: Habif TP, ed.Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 5th ed. Philadelphia, PA: Mosby/Elsevier, 2010:443-456.
  7. Elmets CA. Management of common superficial fungal infections in patients with AIDS.J Am Acad Dermatol. 1994;31(3 Pt 2):s60-s63.
  8. Rosen T, Martin S. Tinea versicolor. In: Rosen T, Martin S, eds. Atlas of Black Dermatology. Boston, MA: Little, Brown and Company, 1981:52-53.
  9. Ray T. Cutaneous and disseminated skin manifestations of candidiasis. In: Elewski BE, ed.Cutaneous Fungal Infections. New York: Igaku-Shoin Medical Publishers, 1992:84-105.
  10. Jautová J, Virágová S, Ondrasovic M, Holoda E. Incidence of Candida species isolated from human skin and nails: a survey.Folia Microbiol (Praha). 2001;46(4):333-337.
  11. Walsh TJ, Dixon DM. Spectrum of mycoses. In: Baron S, ed.Medical Microbiology. 4th ed. Galveston, TX: University of Texas Medical Branch at Galveston, 1996:Chp 75. Available from: http://www.ncbi.nlm.nih.gov/books/NBK7902/. Accessed August 30, 2013.
  12. Itin PH, Battegay M. Skin problems in immunodeficient patients. Curr Probl Dermatol. 2012;43:9-17.
  13. Grover C, Khurana A. An update on treatment of onychomycosis.Mycoses.2012;55(6):541-551.
  14. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC.Prevalence and epidemiology of onychomycosis in patients visiting physicians'offices: a multicenter Canadian survey of 15,000 patients.J Am Acad Dermatol. 2000;43(2 Pt 1):244-248.
  15. Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies.J Am Acad Dermatol. 1997;36(3 Pt 1):395-402.
  16. Elewski BE. Superficial mycoses, dermatophytoses, and selected dermatomycoses. In: Elewski BE, ed.Cutaneous Fungal Infections. New York: Igaku-Shoin Medical Publishers, 1992:12-59.
  17. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003;21(3):395-400.
  18. Daniel CR 3rd, Gupta AK, Daniel MP, Daniel CM. Two feet-one hand syndrome:a retrospective multicenter survey.Int J Dermatol. 1997;36(9):658-660.
  19. Gupta AK, Chow M, Daniel CR, Aly R. Treatments of tinea pedis.Dermatol Clin. 2003;21(3):431-462.
  20. Ansar A, Farshchian M, Nazeri H, Ghiasian SA. Clinico-epidemiological and mycological aspects of tinea incognito in Iran: A 16-year study.Med Mycol J.2011;52(1):25-32.
  21. Kobayashi M, Ishida E, Yasuda H, Yamamoto O, Tokura Y. Tinea profunda cysticum caused by Trichophyton rubrum. J Am Acad Dermatol. 2006;54(suppl 2):s11-s13.
  22. Zaias N. Tinea pedis interdigitalis (interspace).Cutis. 2001;67(suppl 5):28-31.
  23. Zaias N, Rebell G. Chronic dermatophytosis syndrome due to Trichophyton rubrum.Int J Dermatol. 1996;35(9):614-617.
  24. Zaias N, Rebell G. Clinical and mycological status of the Trichophyton mentagrophytes (interdigitale) syndrome of chronic dermatophytosis of the skin and nails. Int J Dermatol. 2003;42(10):779-788.
  25. Sharma R, de Hoog S, Presber W, Gräser Y. A virulent genotype of Microsporum canis is responsible for the majority of human infections. J Med Microbiol. 2007;56(Pt 10):1377-1385.
  26. Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NL, Correr CJ. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149(3):341-349.
  27. Crawford F. Athlete’s foot. In: Williams H, Bigby M, Diepgen T, Herxheimer A,Naldi L, and Rzany B, eds.Evidence-based Dermatology. 2nd ed. Malden, MA: Blackwell Publishing, 2008:358-361.
  28. Phillips R, Rosen T. Topical antifungal agents. In: Wolverton SE, ed.Comprehensive Dermatologic Therapy. 3rd ed. Philadelphia, PA: Elsevier Saunders, 2013:46-472.
  29. Naftin® (naftifine hydrochloride) Gel, 1% [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2004.
  30. Naftin® (naftifine hydrochloride) Cream, 2% [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2012.
  31. Monk JP, Brogden RN. Naftifine. A review of its antimicrobial activity andtherapeutic use in superficial dermatomycoses. Drugs. 1991;42(4):659-672.
  32. Gupta AK, Ryder JE, Cooper EA. Naftifine: a review.J Cutan Med Surg.2008;12(2):51-58.
  33. Nolting S. Investigation of the antibacterial effect of the antifungal agent naftifine: left versus right clinical comparative study between naftifine and gentamicin in pyoderema.Mykosen. 1987;30(suppl 1):70-77.
  34. Petranyi G, Georgopoulos A, Mieth H. In vivo antimycotic activity of naftifine.Antimicrob Agents Chemother. 1981;19(3):390-392.
  35. Kagawa S. Comparative clinical trial of naftifine and clotrimazole in tinea pedis, tinea cruris, and tinea corporis. Mykosen. 1987;30(suppl 1):63-69.
  36. Rietschel RL, Fowler JF. Reactions to topical antimicrobials. In: Rietschel RL, Fowler JF, eds. Fisher’s Contact Dermatitis. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:181.
  37. Kyle AA, Dahl MV. Topical therapy for fungal infections.Am J Clin Dermatol. 2004;5(6):443-451.
  38. Ghannoum M. Study 07-03, Merz Pharmaceuticals LLC, Greensboro, NorthCarolina, 2008.
  39. Ghannoum M. Study 07-02, Merz Pharmaceuticals LLC, Greensboro, North Carolina, 2007.
  40. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis.J Drugs Dermatol. 2011;10(11):1282-1288.
  41. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. 2011;10(10):1142-1147.
  42. Plaum S, Fleischer A, Verma A, et al. Detection and Relevance of Naftifine Hydrochloride in the Stratum Corneum up to Four Weeks Following the Last Application of Naftifine Cream 2%. Poster presented at: South Beach Symposium, Miami Beach, Florida, April 2013.


James Q. Del Rosso DO FAOCDjqdelrosso@yahoo.com